KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma
Titel:
KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma
Auteur:
Mateos, M.V. Blacklock, H. Rocafiguera, A.O. Iida, S. Jagannath, S. Lonial, S. Kher, U. Farooqui, M. Marinello, P. San-Miguel, J.